University Hospital Ramon y Cajal

Madrid 28041

4 studies enrolling now · 12 studies all time

What they study most

Acute Chest Pain, Advanced Malignancies, Advanced Solid Tumor, Anemia, Aspergillus, Atrial Fibrillation, Candidemia, Candidiasis, Invasive, Diffuse Large B Cell Lymphoma, Endometrial Cancer, FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome, Familial Pancreatic Cancer

Studies at this site

• A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions — Recruiting now
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas — Recruiting now
• Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress — Recruiting now
• Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib — Recruiting now
• Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation — Completed
• Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI) — Running, not enrolling
• A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole — Stopped early
• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies — Completed
• Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis — Completed
• ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) — Stopped early
• A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups — Completed
• CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension — Completed